- Home
- OLO vs MLYS Comparison
OLO vs MLYS Comparison
Compare OLO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- MLYS
- Stock Information
- Founded
- OLO 2005
- MLYS 2019
- Country
- OLO United States
- MLYS United States
- Employees
- OLO N/A
- MLYS N/A
- Industry
- OLO Major Banks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- OLO Finance
- MLYS Health Care
- Exchange
- OLO Nasdaq
- MLYS Nasdaq
- Market Cap
- OLO 1.0B
- MLYS 893.0M
- IPO Year
- OLO 2021
- MLYS 2023
- Fundamental
- Price
- OLO $8.65
- MLYS $14.65
- Analyst Decision
- OLO Buy
- MLYS Strong Buy
- Analyst Count
- OLO 3
- MLYS 3
- Target Price
- OLO $9.00
- MLYS $33.00
- AVG Volume (30 Days)
- OLO 1.5M
- MLYS 650.3K
- Earning Date
- OLO 05-08-2025
- MLYS 05-12-2025
- Dividend Yield
- OLO N/A
- MLYS N/A
- EPS Growth
- OLO N/A
- MLYS N/A
- EPS
- OLO 0.01
- MLYS N/A
- Revenue
- OLO $299,107,000.00
- MLYS N/A
- Revenue This Year
- OLO $18.70
- MLYS N/A
- Revenue Next Year
- OLO $18.20
- MLYS N/A
- P/E Ratio
- OLO $807.33
- MLYS N/A
- Revenue Growth
- OLO 23.31
- MLYS N/A
- 52 Week Low
- OLO $4.20
- MLYS $8.24
- 52 Week High
- OLO $8.35
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- OLO 84.46
- MLYS 53.36
- Support Level
- OLO $6.99
- MLYS $14.03
- Resistance Level
- OLO $6.39
- MLYS $15.79
- Average True Range (ATR)
- OLO 0.32
- MLYS 0.99
- MACD
- OLO 0.24
- MLYS 0.10
- Stochastic Oscillator
- OLO 93.80
- MLYS 57.57
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.